Form 4: Novavax EVP Robert Walker Receives Equity Grant

Novavax EVP of R&D Robert Walker was granted 99,500 stock options and 66,000 restricted stock units on April 14, 2026.

Summary

• Robert Edward Walker, EVP of R&D at Novavax, Inc., received a new equity compensation package.
• The grant includes 99,500 stock options with an exercise price of $8.46.
• The grant includes 66,000 restricted stock units (RSUs), each representing a right to one share of common stock.
• The awards were issued under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard executive compensation practices rather than a change in company strategy or financial health.

Positives

• Equity grants align the interests of the EVP of R&D with long-term shareholder value.
• Vesting schedules for both options and RSUs are tied to continued employment, promoting executive retention.

Negatives

• The issuance of new equity awards results in potential future dilution for existing shareholders.

Risks

• Vesting is contingent upon continued employment, creating potential turnover risk if the executive departs.
• The value of the stock options is dependent on the future market performance of NVAX common stock.

Future Outlook

The equity grants are subject to multi-year vesting schedules, with options vesting over four years and RSUs vesting over three years, contingent on continued service.

Management Comments

• No specific management commentary was provided in this regulatory filing.

Industry Context

StockSavvy.ai notes that equity-based compensation for R&D leadership is standard practice in the biotechnology sector to incentivize long-term drug development milestones and clinical trial success.

Comparison to Industry Standards

• The use of a mix of stock options and RSUs is consistent with standard executive compensation structures in the mid-cap biotech industry.
• Vesting periods of 3-4 years align with typical industry retention strategies for C-suite and EVP-level personnel.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise and vesting of these equity awards.

Next Steps

• Vesting of 25% of stock options on April 14, 2027.
• Vesting of one-third of RSUs on April 14, 2027.

Key Dates

Keywords

Novavax, NVAX, Form 4, Executive Compensation, Stock Options, Restricted Stock Units, Insider Trading